LJPC up +8.31% percent Today $LJPC High is at 13.66 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
LJPC up +8.31% percent Today $LJPC High is at 13.66 and the Low 12.30 with current volume of 191,018.

Recent News posted below.

La Jolla Pharma LJPC other info.
http://investorshangout.com/La-Jolla-Pharmace...JPC-63793/

LJPC La Jolla Pharma Recent Headline News

La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 69.16 (+0.20), LCI: 51.37 (+1.20), BCRX: 10.93 (+0.47), LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 13.45 (+1.17), CEMP: 13.86 (+0.10), IG: 9.57 (+0.12), BIOD: 1.51 (-0.03)

5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 13.45 (+1.17), IPCM: 38.75 (-0.35), EGBN: 34.92 (+0.11), CSL: 88.94 (+0.19)

La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that an abstract of the results for the Company's Phase 2 clinical trial of GCS-100 in chronic kidney disease (CKD) has been selected by the American Society of Nephrology's (ASN) Program Committee for poster presentation at the Kidney Week Annual Meeting. Kidney Week will be held November 11-16, 2014 in Philadelphia, Pennsylvania.
LJPC: 13.45 (+1.17)

La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 13.45 (+1.17)

La Jolla (LJPC) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:43AM CDT
La Jolla (LJPC) is Oversold: Can It Recover?
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
Business Wire - Mon Sep 08, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City.
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome
Business Wire - Mon Aug 25, 7:04AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Thu Aug 14, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation
Business Wire - Thu Aug 14, 7:00AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office ("USPTO" has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons.
LJPC: 13.45 (+1.17)

Is ViaSat (VSAT) Poised to Surprise Q1 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 11:50AM CDT
Satellite communications company ViaSat Inc. (VSAT), is set to release its first-quarter fiscal 2015 financial numbers after the closing bell on Aug 12, 2014.
CPG: 31.98 (-0.55), LJPC: 13.45 (+1.17), JCP: 7.28 (-0.54), VSAT: 63.00 (-2.39)

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference
Business Wire - Mon Aug 11, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City.
LJPC: 13.45 (+1.17)

Galectin Drug is a Fatty Liver Flop
at The Street - Tue Jul 29, 9:26AM CDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
LJPC: 13.45 (+1.17), GALT: 4.90 (-0.38)

La Jolla Pharmaceutical Company Closes Offering of Common Stock
Business Wire - Mon Jul 28, 5:29PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters' option to purchase up to an additional 720,000 shares of common stock. Gross offering proceeds are approximately $56.6 million, including proceeds from the partial exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
LJPC: 13.45 (+1.17)

4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
ACRX: 6.00 (-0.04), OMED: 20.08 (-0.11), LJPC: 13.45 (+1.17), LGND: 54.42 (+0.48)

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jul 23, 8:14AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jul 22, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla.
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company Analyst Initiation of Coverage: Steer Clear of this Company with a History of Failure by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biopharmaceutical company focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. The company's main product candidates include GCS-100 for the treatment of chronic kidney disease (CKD), LJPC-501 that is designed to help restore kidney function in patients with hepatorenal syndrome (HRS), and LJPC-401 for the treatment of iron disorders. In addition, LJPC is also developing LJPC-1010, which is an oral derivative of GCS-100 for the treatment of non-alcoholic steatohepatitis (NASH). Further, LJPC is also engaged in pre-clinical testing for LJPC-201 for hepatic fibrosis and LJPC-101 for end-stage renal disease (ESRD).
LJPC: 13.45 (+1.17)

Will La Jolla (LJPC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:48AM CDT
Will La Jolla (LJPC) Continue to Surge Higher?
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)
Business Wire - Tue Jul 15, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.
LJPC: 13.45 (+1.17)

La Jolla Pharmaceutical Company. (LJPC) Stock Research Links

LJPC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Insiders Buy Up on MicroStrategy While Analysts Expect Growth

Updated Category News Views 198

Insider Purchases Indicate Confidence in MicroStrategy Recently, insiders at MicroStrategy Incorporated (NASDAQ: MSTR) have made notable stock purchases that are turning heads in the financial community. Even though there were increases in insider share sales in the last quarter, which reached a two-year peak, the market has not reacted unfavorably. Most of these sales...

Continue Reading
Burlington Stores Insider Transaction: Stephen Ferroni's Move

Updated Category News Views 174

Burlington Stores Insider Transaction Details In a significant move recently disclosed in an SEC filing, Stephen Ferroni, the Senior Vice President at Burlington Stores, made headlines by exercising company stock options. This transaction, involving the exercise of options for 1,123 shares, amounted to a transaction value of approximately $200,331. The filing highlights...

Continue Reading
Clairvest Group's Strategic Acquisition of MGM Northfield Park

Updated Category News Views 371

Clairvest Group Expands Horizons with MGM Northfield Park Acquisition Exciting developments are shaping the landscape for Clairvest Group Inc. as they embark on a significant acquisition journey with MGM Northfield Park. This strategic move not only highlights Clairvest's commitment to growth in the gaming sector but also enhances their longstanding reputation for...

Continue Reading
Innovent Biologics Showcases Promising Research at ADA 85th Sessions

Updated Category News Views 576

Innovent Biologics Presents Cutting-Edge Research at ADA Innovent Biologics, Inc. (HKEX: 01801) has made significant advancements in the biopharmaceutical industry, focusing on innovative treatments for oncology, autoimmune diseases, and metabolic conditions. Recently, the company announced that it will showcase exciting results from its research pipeline at the American...

Continue Reading
Promising Results from HERIZON-GEA-01 Trial Support Ziihera®

Updated Category News Views 288

Encouraging HERIZON-GEA-01 Phase 3 Findings Reinforce Ziihera®’s Role Ziihera, when combined with chemotherapy, has demonstrated a significant improvement in progression-free survival (PFS) compared to trastuzumab and chemotherapy combinations. It also showed a strong trend towards enhancing overall survival (OS) at the first analysis. Clinical Outcomes of Ziihera in...

Continue Reading